+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2025-2030- Product Image
Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2025-2030- Product Image
Sale

Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081619
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Chronic Myeloid Leukemia (CML) represents a dynamic therapeutic area defined by evolving standards of care, with decision-makers facing rapid innovation and shifting regulatory requirements. Effective strategies require navigating supply chain complexities, regional disparities, tariff changes, and advancing therapeutic modalities for each disease phase.

Market Snapshot of the Chronic Myeloid Leukemia Therapeutics Sector

The CML therapeutics market is characterized by distinct treatment modalities, a phased disease progression, and regionally variable adoption rates. Growth is fueled by continuous advancements in tyrosine kinase inhibitors (TKIs), incorporation of precision medicine, and expansion of digital health solutions. Regulatory developments and changes to international trade policies influence both access and affordability across global regions. Key players are responding with enhanced clinical pipelines, supply chain resilience initiatives, and new strategic partnerships to sustain momentum and address unmet needs.

Scope & Market Segmentation for Chronic Myeloid Leukemia Therapeutics

This report systematically analyzes the CML market by treatment type, disease phase, clinical setting, patient age group, region, and leading organizations. Segmentation provides clear visibility into unique challenges and opportunities along the therapeutic journey.

  • Treatment Types: Chemotherapy, stem cell transplantation, tyrosine kinase inhibitors (including first, second, and third generation agents such as bosutinib, dasatinib, nilotinib), with each type suited to particular clinical scenarios and resistance patterns.
  • Phases of Disease: Chronic, accelerated, and blast crisis, each requiring tailored therapeutic and monitoring strategies.
  • Treatment Settings: Hospital inpatient, hospital outpatient, and specialty clinic environments facilitate varying levels of care intensity and patient monitoring.
  • Patient Age Groups: Adult, geriatric, and pediatric populations have distinct dosing, toxicity, and supportive care requirements.
  • Regions: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Viatris Inc., Intas Pharmaceuticals Limited, Cipla Limited, Dr. Reddy’s Laboratories Limited.

Key Takeaways for Senior Decision-Makers

  • Therapeutic innovations, particularly next-generation tyrosine kinase inhibitors, are redefining clinical pathways by increasing molecular response rates and extending duration of remission in CML.
  • The rise of precision medicine and digital monitoring tools is transforming patient management, enabling tailored dosing and proactive intervention as individual needs evolve.
  • Global supply chain strategies are shifting to mitigate new tariff-related disruptions, prompting diversification and local manufacturing to ensure secure access to essential medicines.
  • Geographic heterogeneity in regulatory procedures and reimbursement affects market entry, with mature North American and Western European markets displaying strong adoption, while emerging markets focus on access and capacity building.
  • Collaborations across academia, biopharma, and contract manufacturers accelerate the translation of research into practice, supporting continuous therapeutic innovation and market resilience.
  • Comprehensive patient engagement and economic modeling are rising priorities for stakeholders aiming to demonstrate long-term value and differentiate within a competitive landscape.

Tariff Impact on CML Supply Chains and Costs

United States tariffs introduced in 2025 have prompted pharmaceutical companies to reevaluate sourcing and procurement of active ingredients used in CML therapies. These trade measures have driven localized manufacturing partnerships and strategic stockpiling efforts, aiming to buffer hospitals and clinics from potential shortages and cost volatility. Regulatory bodies are expediting approvals of domestic generics in response, striving to maintain treatment continuity and market stability.

Research Methodology & Data Sources

This report employs a stepwise methodology combining secondary research from scientific literature, regulatory files, and clinical trial registries with primary insights from interviews with hematologists, pharmacists, and supply chain analysts. Quantitative and qualitative findings are triangulated and validated through panel peer review, assuring data reliability and segment accuracy.

Why This Report Matters for Industry Leaders

  • Strategic segmentation and benchmarking enable precise investment, R&D prioritization, and market entry planning for phase-specific CML management.
  • Decision-makers gain actionable intelligence to adapt operational approaches, improve supply chain resilience, and navigate evolving regulatory and tariff challenges.
  • Comprehensive insights support alignment between clinical innovation, policy advocacy, and patient engagement—driving differentiated value in a complex, competitive market.

Conclusion

Senior leaders equipped with this analysis can proactively address CML’s evolving complexities, align strategies with emerging trends, and foster sustainable advantages amid regulatory, clinical, and operational transformation.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing use of second and third generation tyrosine kinase inhibitors to overcome resistance in chronic phase CML
5.2. Emergence of combination therapies integrating TKIs with immunomodulatory agents to deepen molecular response in advanced phase CML
5.3. Growing adoption of treatment discontinuation protocols in sustained deep molecular remission in chronic phase CML
5.4. Implementation of digital monitoring platforms for real time adherence and molecular response tracking in CML management
5.5. Rising significance of real world evidence studies evaluating long term safety and efficacy of generic imatinib in chronic phase CML
5.6. Development of novel BCR-ABL1 allosteric inhibitors to target resistant mutants in accelerated and blast phase CML
5.7. Increasing patient stratification using next generation sequencing to guide personalized therapy in all phases of CML
5.8. Heightened focus on cost effectiveness and value based pricing models for emerging CML treatments across different healthcare systems
5.9. Integrating minimal residual disease assessments with molecular imaging for precision management in late phase CML
5.10. Advancement in CAR T cell and bispecific antibody approaches as potential salvage therapies in blast phase CML
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.3. Stem Cell Transplantation
8.4. Tyrosine Kinase Inhibitor
8.4.1. First Generation TKI
8.4.2. Second Generation TKI
8.4.2.1. Bosutinib
8.4.2.2. Dasatinib
8.4.2.3. Nilotinib
8.4.3. Third Generation TKI
9. Treating Chronic Myeloid Leukemia by Phase Market, by Phase
9.1. Introduction
9.2. Accelerated Phase
9.3. Blast Crisis
9.4. Chronic Phase
10. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Setting
10.1. Introduction
10.2. Hospital Inpatient
10.3. Hospital Outpatient
10.4. Specialty Clinic
11. Treating Chronic Myeloid Leukemia by Phase Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Americas Treating Chronic Myeloid Leukemia by Phase Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novartis AG
15.3.2. Bristol-Myers Squibb Company
15.3.3. Pfizer Inc.
15.3.4. Takeda Pharmaceutical Company Limited
15.3.5. Teva Pharmaceutical Industries Limited
15.3.6. Sun Pharmaceutical Industries Limited
15.3.7. Viatris Inc.
15.3.8. Intas Pharmaceuticals Limited
15.3.9. Cipla Limited
15.3.10. Dr. Reddy’s Laboratories Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET: RESEARCHAI
FIGURE 24. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET: RESEARCHSTATISTICS
FIGURE 25. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET: RESEARCHCONTACTS
FIGURE 26. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 86. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 87. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 88. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 89. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 90. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 91. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 92. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 93. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 94. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 95. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 96. CANADA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 97. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 100. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 101. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 102. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 103. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 106. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 107. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. MEXICO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 160. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 161. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 162. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 163. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 164. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 165. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 168. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 169. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. GERMANY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 172. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 173. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 174. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 175. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 176. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 177. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 180. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 181. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. FRANCE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 195. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 198. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 199. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 200. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 201. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 202. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 203. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 204. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 205. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 206. ITALY TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 207. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 210. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 211. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 212. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 213. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 216. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 217. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 218. SPAIN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 255. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2024 (USD MILLION)
TABLE 258. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2025-2030 (USD MILLION)
TABLE 259. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2024 (USD MILLION)
TABLE 260. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2025-2030 (USD MILLION)
TABLE 261. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 264. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 265. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. DENMARK TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Treating Chronic Myeloid Leukemia by Phase market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
  • Intas Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited

Related Topics

Related Reports

TKI for Chronic Myeloid Leukemia Market - Global Forecast 2025-2030 - Product Image

TKI for Chronic Myeloid Leukemia Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Leukemia Targeted Therapy Drugs Market - Global Forecast 2025-2030 - Product Image

Leukemia Targeted Therapy Drugs Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Chronic Myeloid Leukemia - Pipeline Insight, 2025 - Product Image

Chronic Myeloid Leukemia - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Leukemia Therapeutics Market Report 2025 - Product Image

Leukemia Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Acute Myeloid Leukemia Market Report and Forecast 2025-2034 - Product Image

Acute Myeloid Leukemia Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.